- Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming ...
- Polyplus-transfection SA, a privately-held company developing innovative ...
- Polyplus-transfection SA, a privately-held company developing innovative solutions for the delivery ...
- - The Additional Funds Will Enable the Company to Expand its Therapeutic ...